Phase 2SuspendedGeroscience intervention
Inflammation and Stem Cells in Diabetic and Chronic Kidney Disease
Frailty, Inflammation, and Stem Cell Functionality in Chronic Kidney Disease
- Sponsor
- Mayo Clinic (Academic or other)
- Enrollment
- 30 planned
- Conditions
- Chronic Kidney Diseases; Diabetes Mellitus; Diabetic Nephropathies
- Interventions
- Fisetin; Placebo oral capsule
- Ages
- adults, older adults
- Registry
- NCT03325322
Full record on ClinicalTrials.gov
From the registry
The proposed studies will examine the effect of fisetin on adipose tissue-derived mesenchymal stem/stromal cell function, kidney function, markers of inflammation, and physical function in individuals with advanced chronic kidney disease.
Primary outcomes
- Change in inflammatory markers including C-reactive protein
- Effect on Mesenchymal stem cell function including cell migration
History
Primary completion expected
Last registry update
Started
Registered